GO:0060193 positive regulation of lipase activity: Lipid Signaling Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0060193 (positive regulation of lipase activity) describes any biological process that increases the frequency, rate, or extent of lipase-catalyzed lipid hydrolysis.
• Lipases such as LPL, LIPE, PNPLA2, and LIPG are central enzymes whose activity is tightly controlled by hormones, apolipoproteins, and nutritional status.
• Dysregulated positive regulation of lipase activity contributes to obesity, non-alcoholic fatty liver disease, cardiovascular disease, and cancer-associated cachexia.
• Key molecular regulators include ANGPTL3, ANGPTL4, ANGPTL8, FGF21, and kallistatin, which modulate lipase activity in a tissue-specific manner.
• CRISPR knockout, point-mutation, knock-in, and overexpression models enable causal interrogation of genes that positively regulate lipase activity in metabolic and cancer biology.
• Studying GO:0060193 requires integrating biochemical lipase assays, lipidomics, transcriptomics, and in vivo metabolic phenotyping to capture dynamic regulation.
Description
Positive regulation of lipase activity (GO:0060193) is a biological process that increases the frequency, rate, or extent of lipase activity, defined as the hydrolysis of a lipid or phospholipid. Lipases are enzymes that cleave ester bonds in triglycerides, phospholipids, and other lipids, releasing free fatty acids and glycerol or lysophospholipids. This process is fundamental to energy homeostasis, lipid signaling, and membrane remodeling, and its dysregulation is implicated in a wide range of metabolic and inflammatory diseases. Researchers study GO:0060193 to understand how cells mobilize stored fat, how circulating lipoproteins are remodeled, and how tumors and immune cells reprogram lipid metabolism. The positive regulation of lipase activity is orchestrated by a complex network of hormones, apolipoproteins, and intracellular signaling pathways that respond to nutritional and stress cues. Because lipase activity is a central node in lipid metabolism, it represents a promising target for therapeutic intervention in obesity, cardiovascular disease, and cancer. This article synthesizes authoritative QuickGO annotation and verified PubMed literature to provide a research-grade overview of GO:0060193, its key genes, regulatory mechanisms, disease links, and experimental models for functional studies.
positive regulation of lipase activity At A Glance
| GO ID | GO:0060193 |
|---|---|
| GO term | positive regulation of lipase activity |
| Ontology | biological_process |
| Synonym | none |
| Major function | Increases the rate of lipid hydrolysis by lipases, mobilizing fatty acids for energy and signaling |
| Key enzymes | LPL, LIPE, PNPLA2, LIPG, pancreatic lipase |
| Key regulators | ANGPTL3, ANGPTL4, ANGPTL8, FGF21, kallistatin |
| Associated diseases | Obesity, NAFLD, cardiovascular disease, cancer cachexia |
| Research methods | Lipase activity assays, lipidomics, CRISPR screens, metabolic phenotyping |
What Is GO:0060193?
GO:0060193, positive regulation of lipase activity, is defined as any process that increases the frequency, rate, or extent of lipase activity, the hydrolysis of a lipid or phospholipid. In practical terms, it encompasses signaling events, protein-protein interactions, and post-translational modifications that enhance the catalytic action of lipases such as lipoprotein lipase (LPL), hormone-sensitive lipase (LIPE), adipose triglyceride lipase (PNPLA2), and endothelial lipase (LIPG). This regulation can occur at multiple levels, including enzyme abundance, subcellular localization, and allosteric modulation by cofactors like apolipoproteins and ANGPTL proteins.
Why Is positive regulation of lipase activity Important in Cell Biology?
Positive regulation of lipase activity is critical for maintaining energy balance and lipid homeostasis. It controls the release of free fatty acids from adipose tissue and lipoproteins, which are essential substrates for mitochondrial oxidation and precursors for signaling lipids. Dysregulation of this process contributes to hypertriglyceridemia, insulin resistance, hepatic steatosis, and atherosclerosis. In cancer, tumor-associated adipocytes can drive lipolysis to support tumor growth and immune evasion. Understanding the molecular players that positively regulate lipase activity is therefore essential for developing targeted therapies for metabolic and oncologic diseases.
• Controls energy mobilization from adipose tissue and circulating lipoproteins.
• Regulates fatty acid availability for mitochondrial respiration and thermogenesis.
• Modulates lipoprotein remodeling and cardiovascular risk.
• Influences hepatic lipid accumulation and non-alcoholic fatty liver disease progression.
• Supports cancer cell metabolism and immune evasion in the tumor microenvironment.
• Affects retinal lipid homeostasis and age-related macular degeneration.
• Provides targets for drug development in dyslipidemia and obesity.
• Serves as a biomarker for metabolic and inflammatory states.
• Integrates hormonal and nutritional signals via FGF21 and ANGPTL proteins.
• Enables CRISPR-based functional genomics of lipid metabolism.
What Happens During positive regulation of lipase activity?
Signal Initiation and Hormonal Cues
In simple terms: Hormones and nutrients tell the cell to start breaking down fat.
Positive regulation of lipase activity begins with extracellular signals such as catecholamines, natriuretic peptides, and FGF21 that bind to receptors on adipocytes or other cells. These signals activate intracellular kinases like PKA and AMPK, which phosphorylate lipases and their coactivators, leading to increased catalytic activity. In parallel, nutritional status modulates the secretion of ANGPTL proteins that inhibit or enhance lipase activity in a tissue-specific manner.
Lipase Activation and Recruitment
In simple terms: The lipase enzyme is switched on and moved to the fat droplet.
Upon phosphorylation, hormone-sensitive lipase (LIPE) translocates from the cytosol to lipid droplets, where it hydrolyzes diacylglycerols and cholesteryl esters. Adipose triglyceride lipase (PNPLA2) is activated by comparative gene identification-58 (CGI-58) and associates with lipid droplets to catalyze the first step of triglyceride hydrolysis. Lipoprotein lipase (LPL) is activated by apolipoprotein C-II and anchored to endothelial surfaces by GPIHBP1, where it hydrolyzes triglycerides in chylomicrons and VLDL.
Amplification and Crosstalk
In simple terms: Multiple signals work together to boost fat breakdown.
Positive regulation often involves amplification loops where initial lipolysis products, such as free fatty acids, activate PPARs and other transcription factors that upregulate lipase gene expression. FGF21, secreted by the liver, enhances adipose lipolysis and energy expenditure, while ANGPTL4 inhibits LPL in a feedback manner. Kallistatin has been shown to promote lipolysis in hepatocytes, contributing to NAFLD progression.
Termination and Feedback
In simple terms: The process is shut down when fat levels are restored or energy demands change.
Termination of positive regulation occurs through dephosphorylation of lipases by phosphatases, degradation of activating hormones, and re-esterification of fatty acids. Insulin signaling opposes lipolysis by activating phosphodiesterase-3B, which reduces cAMP and PKA activity. ANGPTL3, ANGPTL4, and ANGPTL8 form complexes that inhibit LPL under fed conditions, providing a feedback brake on lipase activity.
Key Genes Involved in GO:0060193 positive regulation of lipase activity
The following genes and proteins are central to the positive regulation of lipase activity, based on verified literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| LPL | Hydrolyzes triglycerides in chylomicrons and VLDL; activated by apoC-II | Cardiovascular disease, hypertriglyceridemia |
| LIPE | Hormone-sensitive lipase; catalyzes diacylglycerol and cholesteryl ester hydrolysis | Obesity, lipolysis regulation |
| PNPLA2 | Adipose triglyceride lipase; rate-limiting for triglyceride hydrolysis | Lipid droplet metabolism, AMD |
| LIPG | Endothelial lipase; phospholipase activity on HDL | Cardiovascular risk, HDL metabolism |
| ANGPTL3 | Inhibits LPL; regulates plasma triglycerides | Dyslipidemia, coronary artery disease |
| ANGPTL4 | Inhibits LPL; modulates lipid partitioning | Diabetes, inflammation, cardiovascular mortality |
| ANGPTL8 | Forms complexes with ANGPTL3/4 to regulate LPL | Triglyceride metabolism |
| FGF21 | Promotes lipolysis and energy expenditure | Cancer cachexia, metabolic disease |
| Kallistatin | Promotes lipolysis in hepatocytes | NAFLD progression |
| CGI-58 | Coactivator of PNPLA2; stimulates triglyceride hydrolase activity | Neutral lipid storage disease |
| GPIHBP1 | Anchors LPL to endothelial cells; enhances lipolysis | Hypertriglyceridemia |
| APOC2 | Activates LPL; cofactor for triglyceride hydrolysis | Familial chylomicronemia |
| APOA5 | Enhances LPL-mediated lipolysis | Hypertriglyceridemia |
| PPARG | Transcription factor upregulating lipase genes | Insulin sensitivity, adipogenesis |
| PNPLA3 | Lipase-like protein associated with hepatic steatosis | NAFLD, liver fibrosis |
| BRAF | Oncogenic kinase influencing autophagy and lipid metabolism | Thyroid carcinoma, melanoma |
| LIPA | Lysosomal acid lipase; hydrolyzes cholesteryl esters | Wolman disease, CESD |
How Is positive regulation of lipase activity Regulated?
Positive regulation of lipase activity is controlled by a network of hormonal, nutritional, and transcriptional signals. Insulin suppresses lipolysis by activating phosphodiesterase-3B, which degrades cAMP and reduces PKA-mediated phosphorylation of LIPE and PNPLA2. Catecholamines and natriuretic peptides stimulate lipolysis via PKA and PKG signaling. FGF21, secreted in response to fasting or stress, enhances adipose lipolysis and energy expenditure. ANGPTL3, ANGPTL4, and ANGPTL8 are key inhibitors of LPL, and their expression is regulated by nutritional status, with ANGPTL4 induced by fasting and ANGPTL8 by feeding. Kallistatin promotes hepatic lipolysis and is elevated in NAFLD. At the transcriptional level, PPARγ and PPARα upregulate lipase genes in adipocytes and hepatocytes, respectively. Post-translational modifications, including phosphorylation and ubiquitination, also modulate lipase stability and activity.
positive regulation of lipase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| LPL | Hypertriglyceridemia, cardiovascular disease | Knockout mouse, overexpression in hepatocytes |
| PNPLA2 | Neutral lipid storage disease, AMD | Knockout mouse, point mutation (S47A) |
| ANGPTL3 | Dyslipidemia, coronary artery disease | Knockout rat, humanized knock-in |
| Kallistatin | NAFLD | Overexpression in liver, knockout mouse |
| FGF21 | Cancer cachexia, obesity | Knockout mouse, transgenic overexpression |
Obesity and Metabolic Syndrome
Dysregulated positive regulation of lipase activity contributes to obesity and metabolic syndrome by altering fatty acid flux and energy storage. Excessive lipolysis in visceral adipose tissue releases free fatty acids that promote insulin resistance and ectopic fat deposition. ANGPTL3, ANGPTL4, and ANGPTL8 variants are associated with altered LPL activity and plasma triglyceride levels, influencing diabetes and cardiovascular mortality. FGF21-driven lipolysis in cancer-associated adipocytes impairs CD8+ T cell function, linking lipid mobilization to immune dysfunction.
Non-Alcoholic Fatty Liver Disease (NAFLD)
Elevated kallistatin promotes NAFLD occurrence and progression by enhancing hepatic lipolysis and lipid accumulation. PNPLA3 variants are strongly associated with hepatic steatosis and fibrosis, although the precise mechanism remains under investigation. Positive regulation of lipase activity in hepatocytes contributes to the release of free fatty acids that drive inflammation and fibrosis.
Cardiovascular Disease
LPL activity is a major determinant of plasma triglyceride levels and cardiovascular risk. ANGPTL3, ANGPTL4, and their complexes with ANGPTL8 are associated with LPL activity, coronary artery calcification, and coronary events. Endothelial lipase (LIPG) variants interact with physical activity to modulate cardiovascular disease risk factors. Therapeutic targeting of ANGPTL3 with monoclonal antibodies or siRNA reduces triglycerides and cardiovascular events.
Cancer and Cachexia
Cancer-associated adipocytes mediate CD8+ T cell dysfunction via FGF21-driven lipolysis, highlighting a role for positive regulation of lipase activity in tumor immune evasion. In thyroid carcinoma, autophagy sustains mitochondrial respiration and determines resistance to BRAF(V600E) inhibition, a process that may involve lipid catabolism. Lack of PNPLA2 accelerates age-related macular degeneration-like features in mice, indicating that lipase activity is also important in retinal lipid homeostasis.
From positive regulation of lipase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does gene X positively regulate lipase activity? | CRISPR knockout in adipocytes or hepatocytes |
| Does a specific point mutation alter lipase activity? | CRISPR point mutation (e.g., S47A in PNPLA2) |
| Does a disease-associated variant affect lipase function? | Knock-in of variant allele in cell lines or mice |
| Where is the lipase localized during activation? | Tagged knock-in (e.g., GFP-PNPLA2) |
| Does overexpression of gene X increase lipolysis? | Lentiviral overexpression in 3T3-L1 adipocytes |
| Which genes regulate lipase activity in a genome-wide screen? | CRISPR library screening in lipid droplet-accumulating cells |
How to Study the positive regulation of lipase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Lipase activity assay | Enzymatic hydrolysis rate | Validation of positive regulators |
| Lipidomics (LC-MS) | Lipid species abundance | Global lipid flux analysis |
| CRISPR knockout screen | Gene requirement for lipase activity | Discovery of novel regulators |
| RNA-seq | Transcriptional changes | Pathway analysis after gene perturbation |
| Western blot | Protein expression and phosphorylation | Lipase activation status |
| Immunofluorescence | Subcellular localization | Lipid droplet recruitment |
| Metabolic cage | Energy expenditure, RQ | In vivo phenotyping |
Lipase Activity Assays
Direct measurement of lipase activity using fluorogenic or colorimetric substrates (e.g., 4-methylumbelliferyl oleate) in cell lysates or conditioned media. These assays quantify the hydrolysis rate and are essential for validating positive regulators identified by genetic screens.
Lipidomics and Metabolomics
Mass spectrometry-based lipidomics profiles changes in triglyceride, diacylglycerol, and free fatty acid species following modulation of candidate genes. This approach reveals the impact of positive regulation on lipid flux and identifies signaling lipids.
CRISPR Screens and Functional Genomics
Genome-wide CRISPR knockout or activation screens in lipid droplet-accumulating cell lines (e.g., HepG2, 3T3-L1) can identify genes that positively regulate lipase activity. Hits are validated by targeted knockout and lipase assays.
In Vivo Metabolic Phenotyping
Mouse models with tissue-specific knockout or overexpression of candidate genes are subjected to glucose tolerance tests, insulin tolerance tests, and lipid tolerance tests. These studies link positive regulation of lipase activity to whole-body energy homeostasis.
How CRISPR Can Be Used to Study GO:0060193 positive regulation of lipase activity
Knockout
CRISPR knockout of candidate genes (e.g., PNPLA2, LIPE, ANGPTL3) in adipocytes or hepatocytes abolishes their function, allowing researchers to test whether they are required for positive regulation of lipase activity. Knockout models are essential for establishing causality and are often validated by rescue experiments.
Point Mutation
CRISPR point mutation introduces specific amino acid substitutions (e.g., catalytic serine to alanine in PNPLA2) to dissect the enzymatic activity from scaffolding functions. This approach is valuable for studying disease-associated variants that alter lipase activity without affecting protein stability.
Knock-in
Knock-in of tagged alleles (e.g., GFP-PNPLA2) or disease variants (e.g., PNPLA3 I148M) enables real-time tracking of lipase localization and function in live cells. Knock-in models are also used to humanize mouse genes for drug testing.
Overexpression
CRISPR activation (CRISPRa) or lentiviral overexpression of candidate genes (e.g., FGF21, kallistatin) increases lipase activity and lipid mobilization. Overexpression models are useful for gain-of-function studies and for identifying downstream metabolic consequences.
How EDITGENE Supports positive regulation of lipase activity Research
Researchers studying positive regulation of lipase activity-related genes often need to determine whether a candidate gene is causally involved in lipid hydrolysis or simply correlated with metabolic changes. EDITGENE provides comprehensive CRISPR-based services to accelerate this functional validation.
Contact EDITGENE today to design your custom CRISPR model for positive regulation of lipase activity research.
Frequently Asked Questions About positive regulation of lipase activity
What is GO:0060193?
GO:0060193 is the Gene Ontology term for positive regulation of lipase activity, defined as any process that increases the frequency, rate, or extent of lipase activity, the hydrolysis of a lipid or phospholipid.
What genes are involved in positive regulation of lipase activity?
Key genes include LPL, LIPE, PNPLA2, LIPG, ANGPTL3, ANGPTL4, ANGPTL8, FGF21, and kallistatin.
How is lipase activity positively regulated?
It is regulated by hormonal signals (catecholamines, FGF21), phosphorylation by PKA, and interactions with cofactors like apoC-II and CGI-58.
What diseases are associated with dysregulated lipase activity?
Obesity, non-alcoholic fatty liver disease, cardiovascular disease, and cancer cachexia are linked to altered positive regulation of lipase activity.
What is the role of ANGPTL3 in lipase activity?
ANGPTL3 inhibits lipoprotein lipase, and its inhibition increases lipase activity and lowers plasma triglycerides.
How can CRISPR be used to study positive regulation of lipase activity?
CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in lipid metabolism.
What methods measure lipase activity?
Lipase activity assays, lipidomics, and metabolic phenotyping are commonly used to quantify changes in lipase function.
Is PNPLA2 a positive regulator of lipase activity?
PNPLA2 (ATGL) is a rate-limiting triglyceride lipase; its activation increases lipase activity, and its loss impairs lipolysis.
What is the link between lipase activity and cancer?
Cancer-associated adipocytes drive FGF21-mediated lipolysis, which impairs CD8+ T cell function and supports tumor growth.
How does kallistatin affect lipase activity?
Kallistatin promotes hepatic lipolysis and is elevated in NAFLD, contributing to disease progression.
Conclusion
Positive regulation of lipase activity (GO:0060193) is a fundamental biological process that controls lipid mobilization and energy homeostasis. Its dysregulation is implicated in major metabolic, cardiovascular, and oncologic diseases. Understanding the genes and mechanisms that positively regulate lipase activity provides opportunities for therapeutic intervention. CRISPR-based models and functional genomics are powerful tools to dissect this process and identify new drug targets.
References
- 1. Engin A. 2024. Lipid Storage, Lipolysis, and Lipotoxicity in Obesity.. Adv Exp Med Biol 1460:97-129 PMID: 39287850
- 2. Dalangood S et al.. 2025. Cancer-associated adipocytes mediate CD8(+)T cell dysfunction via FGF21-driven lipolysis.. Cell Rep 44(11):116526 PMID: 41191487
- 3. Fang Z et al.. 2024. Elevated Kallistatin promotes the occurrence and progression of non-alcoholic fatty liver disease.. Signal Transduct Target Ther 9(1):66 PMID: 38472195
- 4. Silbernagel G et al.. 2025. Associations of Circulating ANGPTL3, C-Terminal Domain-Containing ANGPTL4, and ANGPTL3/8 and ANGPTL4/8 Complexes with LPL Activity, Diabetes, Inflammation, and Cardiovascular Mortality.. Circulation 151(3):218-234 PMID: 39392008
- 5. Salazar-Tortosa DF et al.. 2022. Interplay of physical activity and genetic variants of the endothelial lipase on cardiovascular disease risk factors.. Pediatr Res 91(4):929-936 PMID: 33859368
- 6. Díaz-Gago S et al.. 2024. Autophagy sustains mitochondrial respiration and determines resistance to BRAF(V600E) inhibition in thyroid carcinoma cells.. Autophagy 20(6):1383-1397 PMID: 38436206
- 7. Yang J et al.. 2025. Lack of Pnpla2 Accelerates Progression of AMD-Like Features in Mice.. Invest Ophthalmol Vis Sci 66(12):11 PMID: 40900080
- 8. Silbernagel G et al.. 2025. Associations of ANGPTL proteins and complexes with progression of coronary artery calcification and coronary events.. Atherosclerosis 409:120485 PMID: 40819411
